TABLE 1.
Patient Characteristics
| Clinical Value | No CH (n = 24) | CH (≥2%) (n = 13) | Total (n = 37) | P |
|---|---|---|---|---|
| Age, years, median (range) | 68.0 (34.0-81.0) | 69.0 (59.0-85.0) | 68.0 (34.0-85.0) | .60a |
| Male, No. (%) | 14 (58.3) | 5 (38.5) | 19 (51.4) | .25b |
| Primary tumor type, No. (%) | .71b | |||
| Gastric | 1 (4.2) | 0 (0.0) | 1 (2.7) | |
| Head/neck | 0 (0.0) | 1 (7.7) | 1 (2.7) | |
| Other | 2 (8.3) | 1 (7.7) | 3 (8.1) | |
| Pancreatic | 8 (33.3) | 3 (23.1) | 11 (29.7) | |
| Paraganglioma | 1 (4.2) | 1 (7.7) | 2 (5.4) | |
| Small bowel | 12 (50.0) | 7 (53.8) | 19 (51.4) | |
| Grade, No. (%) | .46b | |||
| 1 | 5 (20.8) | 3 (23.1) | 8 (21.6) | |
| 2 | 15 (62.5) | 7 (53.8) | 22 (59.5) | |
| 3 | 2 (8.3) | 0 (0.0) | 2 (5.4) | |
| Unknown | 2 (8.3) | 3 (23.1) | 5 (13.5) | |
| Ki-67%, median (range) | 7.3 (1.0-65) | 8.5 (2.0-20) | 8.5 (1.0-65) | .54a |
| Bone mets, No. (%) | 9 (37.5) | 10 (76.9) | 19 (51.4) | .02b |
| Severity of bone mets, No. (%) | .07b | |||
| None | 15 (62.5) | 3 (23.1) | 18 (48.6) | |
| Mild | 5 (20.8) | 6 (46.2) | 11 (29.7) | |
| Severe | 4 (16.7) | 4 (30.8) | 8 (21.6) | |
| Previous therapy | 6 (25.0) | 5 (38.5) | 11 (29.7) | .39b |
| Alkylating | 2 (8.3) | 1 (7.7) | 3 (8.1) | .95b |
| Platinum mTOR inhibitor | 4 (16.7) | 4 (30.8) | 8 (21.6) | .32b |
| Somatostatin analog | 22 (91.7) | 13 (100) | 35 (94.6) | .28b |
| External radiation | 2 (8.3) | 3 (23.1) | 5 (13.5) | .21b |
| Baseline laboratory tests | ||||
| Hemoglobin (g/dL), median (range) | 13.0 (10.6-16.3) | 13.3 (10.7-15.4) | 13.0 (10.6-16.3) | .57a |
| RDW (%), median (range) | 13.9 (11.9-21.3) | 14.1 (12.4-17.6) | 14.0 (11.9-21.3) | .76a |
| MCV (fL), median (range) | 91.0 (76.5-100.2) | 92.5 (88.7-96.0) | 91.4 (76.5-100.2) | .35a |
| Platelets (×109/L), median (range) | 230.5 (153-473) | 184.5 (113-367) | 220.0 (113-473) | .03a |
| Leukocytes (×109/L), median (range) | 6.4 (4.0-12.7) | 6.0 (2.4-8.8) | 6.1 (2.4-12.7) | .43a |
| Neutrophils (×109/L), median (range) | 4.4 (2.0-10.0) | 3.7 (1.3-7.3) | 3.8 (1.3-10) | .51a |
| Lymphocytes (×109/L), median (range) | 1.3 (0.4-2.3) | 1.5 (0.5-2.0) | 1.4 (0.4-2.3) | .46a |
| Completed four cycles, No. (%) | 17 (70.8) | 8 (61.5) | 25 (67.6) | .56b |
| Total GBq received, median (range) | 789.1 (187-840) | 765.2 (211-841) | 781.2 (187-841) | .17a |
| 12-month laboratory tests | ||||
| Hemoglobin (g/dL), median (range) | 12.1 (7.4-17.0) | 12.6 (9.4-17.2) | 12.5 (7.4-17.2) | .88a |
| RDW (%), median (range) | 14.1 (12.0-21.0) | 13.2 (12.2-16.5) | 14.1 (12.0-21.0) | .29a |
| MCV (fL), median (range) | 97.1 (64.7-111.0) | 97.1 (91.1-101.0) | 97.1 (64.7-111.0) | .77a |
| Platelets (×109/L), median (range) | 169.0 (36.0-264.0) | 199.5 (103.0-427.0) | 172.0 (36.0-427.0) | .43a |
| Leukocytes (×109/L), median (range) | 4.4 (1.8-13.0) | 5.5 (3.6-9.2) | 5.4 (1.8-13.0) | .72a |
| Neutrophils (×/L), median (range) | 2.8 (1.1-5.1) | 4.0 (2.4-4.7) | 2.8 (1.1-5.1) | .16a |
| Lymphocytes (×109/L), median (range) | 0.7 (0.3-2.2) | 0.8 (0.3-2.7) | 0.8 (0.3-2.7) | .60a |
Abbreviations: CH, clonal hematopoiesis; MCV, mean corpuscular volume; mTOR, mammalian target of rapamycin; RDW, red cell distribution width.
a
Wilcoxon rank-sum P value.
b
Chi-square P value.